Skip to main content
Psychedelic State(s) of America
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Biospace

Published November 3, 2026 · Updated November 4, 2026

Compass to submit psilocybin depression drug for approval imminently after stock wobbles

Read the full story at Biospace

Regulatory FDA Psychedelics Depression Earnings · Compass Pathways ... Submit a Press Release · Submit an Event. © 1985 - 2026 BioSpace.com. All.

Post on X

Share this story

Share on XShare on LinkedInShare on FacebookShare on WhatsAppShare on Signal

Surfaced by 2 Google Alerts

  • Psychedelic press release
  • Psychedelics south america